June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
ACE2/ACE-Imbalance in Circulating CD34+ Cells of Individuals with Diabetic Retinopathy
Author Affiliations & Notes
  • Charles A Garcia
    Ophthal-Herman Eye Ctr, Univ of Texas Houston Med Sch, Houston, Texas, United States
    Retinal Vascular Center, Houston, Texas, United States
  • Shrinidh Joshi
    Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota, United States
  • Julio Quiroz-Olvera
    Retinal Vascular Center, Houston, Texas, United States
  • Miguel Duran-Mendez
    Retinal Vascular Center, Houston, Texas, United States
  • Wendy Amparo Cantu-Delgado
    Retinal Vascular Center, Houston, Texas, United States
  • Samuel Gomez
    Retinal Vascular Center, Houston, Texas, United States
  • Stephen Bartelmez
    BetaStem Therapeutics, Sausalito, California, United States
  • Yagna Jarajapu
    Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota, United States
  • Footnotes
    Commercial Relationships   Charles Garcia, None; Shrinidh Joshi, None; Julio Quiroz-Olvera, None; Miguel Duran-Mendez, None; Wendy Cantu-Delgado, None; Samuel Gomez, None; Stephen Bartelmez, None; Yagna Jarajapu, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2526. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Charles A Garcia, Shrinidh Joshi, Julio Quiroz-Olvera, Miguel Duran-Mendez, Wendy Amparo Cantu-Delgado, Samuel Gomez, Stephen Bartelmez, Yagna Jarajapu; ACE2/ACE-Imbalance in Circulating CD34+ Cells of Individuals with Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2526.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Endothelial dysfunction and reduced microvascular repair are the hallmarks of diabetic retinopathy (DR). Bone marrow derived CD34+ cells have the propensity of vascular regeneration. Diabetes is associated with decreased number and vasoreparative dysfunction of CD34+ cells. Angiotensin-converting enzyme (ACE) and ACE2 are primary enzymes of the vascular-detrimental and protective axes of the renin-angiotensin system (RAS), respectively, and are expressed in the vascular endothelium and CD34+ cells. Activation of ACE2 was shown to stimulate vasoreparative functions in CD34+ cells. We tested the hypothesis that balance between ACE and ACE2 shifted towards detrimental axis in CD34+ cells of individuals with DR.

Methods : Peripheral blood was obtained from healthy (control) and diabetic individuals with DR. Mononuclear cells (MNCs) and plasma were separated and lineage- (Lin-) and CD34+ cells isolated. Activities of ACE and ACE2 were determined in plasma and lysates of Lin- and CD34+ cells by using enzyme-selective fluorogenic substrates and inhibitors. Proliferation and migration of cells were determined by using BrdU-ELISA or by chemotaxis assay, respectively.

Results : RESULTS: DR was associated with decreased number of Lin- ((2±0.2)x105, P<0.04) and CD34+ (0.6±0.1)x103, P<0.02) cells (n=6) compared to control group (Lin- (25±4)x105; CD34+ (2±0.4)x103), expressed as per million MNCs. Abundance of both populations is negatively correlated with HbA1C levels (r2=0.9, P<0.01). ACE and ACE2 activities were not different in MNCs. Decreased ACE2 and increased ACE activities were observed in plasma, and CD34+ cell-lysates resulting in reduced ACE2/ACE (DR vs control: Plasma - 0.34±0.07 vs 0.8±0.08, P<0.05; CD34+ - 0.4±0.07 vs 1.8±0.2, P<0.01, n=6). Proliferation of Lin- or CD34+ cells from DR-group was lower in basal conditions or in response to stromal-derived factor-1a (SDF) or vascular endothelial growth factor (VEGF) compared to control (P<0.05 to 0.001, n=4-8). SDF- or VEGF-induced migration of both populations was impaired in DR-group compared to control (n=4-8).

Conclusions : DR decreased the number of circulating Lin- and CD34+ cells and impaired vascular repair due to imbalance in the protective and detrimental axes of RAS. Future trials would offer a unique, minimally invasive treatment for vascular regeneration to those with blinding DR and other diabetic diseases.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×